Planeación y Evaluación de Simulacros
GRUPOS DE TRABAJO DEL COMITÉ DE EMERGENCIAS
Despite the above mentioned limitations, the study has some strengths. First, the longitudinal design of the study allowed for examination of potential predictors of outcome in the Nigerian context.
Third, the assessment of perceived social support using a standard, well validated instrument was an important addition to the literature in Africa.
100
CHAPTER NINE 9.0 RECOMMENDATIONS:
In order to improve the quality of research on outcome of schizophrenia in Nigeria, the author recommends that future researchers in this area in Nigeria should engage in multi-centre studies and include community samples which are better representatives of the general population.
Second, a longer period of follow-up, with probability sampling method for subjects treated in a drug trial setting will add rigor to the outcome investigation.
Third, better strategies to combat attrition which may include home assessment and even telephone interviews may be necessary.
Finally, assessment of neurocognition and extrapyramidal side effects may further clarify the effect of negative symptoms on psychosocial outcome.
101
REFERENCES
1. World Health Organization. International Classification of Diseases and Related Health Problems, 10th edition (ICD-10). Geneva. World Health Organization, 1994.
2. World health Organization. The global burden of diseases 2004 update, Geneva Switzerland: World Health Organization press, 2008.
3. Kraepelin E. Dementia praecox and paraphrenia. Barclay RM translated Huntington, New York: Kreiger RE publishing cooperation, incorporated; 1999.
4. Juckel G, Morosini PL. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Current Opinion in Psychiatry, 2008; 21:630-639.
5. Kebede D, Alem A, Shibre T, Negash A, Deyassa N, Beyero T et al. Short-term symptomatic and functional outcomes of schizophrenia in Butajira, Ethiopia.
Schizophrenia Research, 2005; 78:171-185.
6. Ohaeri JU. Long-term outcome of treated schizophrenia in Nigeria cohort. Retrospective analysis of 7-year follow-up. Journal of Nervous and Mental Disorders, 1993;
181(8):514-516.
7. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex diseases. Science, 2002; 296:692-695.
8. Kebede D, Alem A, Shibre T, Negash A, Deyassa N, Beyero T. Socio-demographic correlates of schizophrenia in Butajira, rural, Ethiopia. Schizophrenia Research, 2004;
69(2):131-141.
9. Marshall M, Lewis D, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Archives of General Psychiatry, 2005; 62:975-983.
10. Puig O, Penades R, Gusto C, Catalan R, Torres A, Salamero M. Verbal memory, negative symptomatology and prediction of psychosocial functioning in schizophrenia. Psychiatry Research, 2008; 158:11-17.
11. Jablensky A, Sartorius N, Ernberg G, Anker M, Cooper JE, Day R et al. Schizophrenia:
manifestation, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine, 1992; 201-297.
12. Eaton WW. Studying the natural history of psychopathology. In: Tsuang MT, Tohen M, Zahner GEP. Textbook of Psychiatric Epidemiology. Wiley, New York, 1995; 157-178.
102
13. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a metanalysis of the outcome literature. American Journal of Psychiatry, 1994; 151(10):1409-1416.
14. Dube K, Kumar N, Dube S. Long-term course and outcome of Agra cases in the International Pilot Study of Schizophrenia. Acta Psychiatrica Scandinavica, 1984;
70:170-179.
15. Sartorius N, Gulbinat W, Harrison G, Lask E, Siegel C. Long-term follow-up of schizophrenia in 16-countries. A description of the International Study of Schizophrenia conducted by the World Health Organization. Social Psychiatry and Psychiatric Epidemiology, 1996; 31:249-258.
16. Sartorius N, Jablensky A, Shapiro L. Two-year follow-up of the patients included in the World Health Organization International Pilot Study of Schizophrenia. Psychological Medicine, 1977; 7:529-541.
17. Gureje O, Bamidele RW. Gender and schizophrenia: association of age at onset with antecedent, clinical, and outcome features. Australia and New Zealand Journal of Psychiatry, 1998; 32(3):415-423.
18. Leff J, Sartorius N, Jablensky A, Korten A, Ernberg G. The International Pilot Study of Schizophrenia: 5-year follow-up findings. Psychological Medicine, 1992; 22:131-145.
19. Gureje O, Cohen A. Differential outcome of schizophrenia: where we are and where we would like to be. British Journal of Psychiatry, 2011; 199:173-175.
20. Craig TJ, Siegel C, Hopper. Outcome in schizophrenia and related disorders compared between developing and developed countries. A recursive partitioning re-analysis of the World Health Organization Determinants of Outcome in Severe Mental Disorders data.
British Journal of Psychiatry, 1997; 170:229-233.
21. Hope K, Wanderling J. Revisiting the developed versus developing country distinction in course and outcome in schizophrenia: results from International Study of Schizophrenia, the World Health Organization collaborative follow-up project. International Study of Schizophrenia. Schizophrenia Bulletin, 2000; 26(4):835-846.
22. Edgerton RB, Cohen A. Culture and schizophrenia: the Determinants of Outcome of Severe Mental Disorders (DOSMED) challenge. British Journal of Psychiatry, 1994;
164:222-231.
23. Cohen A. Prognosis for schizophrenia in the third world: a re-evaluation of cross-cultural research. Culture, Medicine, and Psychiatry, 1992; 16:53-75.
103
24. Cohen A, Patel V, Thara R, Gureje O. Questioning an axiom: better prognosis for schizophrenia in the developing world? Schizophrenia Bulletin, 2008; 34(2): 229-244.
25. Otote DI, Ohaeri JU. Neuropsychiatric features of schizophrenia and their stability in a Nigerian acute admission facility. Psychopathologie africaine, 2000; 3:307-325.
26. Haro JM, Novick D, Bertsch J, Karagianis J, Dossenback M, Jones PB. Cross-national clinical and functional remission rates: Worldwide Schizophrenia Out-patient Health Outcome (S-SOHO) Study. British Journal of Psychiatry, 2011; 199(3):194-201.
27. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling et al. Recovery from psychotic illness: a 15-year and 25-year international follow-up study. British Journal of Psychiatry, 2001; 178:506-517.
Schizophrenia Bulletin, 2009; 35(3):646-654.
29. Teferra S, Shibre T, Fekadu A, Medhin G, Wakwoya A, Alem A et al. Five year clinical course and outcome of schizophrenia in Ethiopia. Schizophrenia Research, 2012;
136(1):137-142.
30. Burton N. Living with schizophrenia. Acheron press, 2012.
31. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts”4. Clinical features and Conceptualization. Schizophrenia research, 2009; 110:1-23.
32. Andreasen NC. Concept of schizophrenia: past, present, and future”, in schizophrenia, Weinberger DR, Harrison PJ, Wiley-Blackwell, Oxford, UK, 3rd edition, 2011.
33. Kendler KS. Phenomenology of schizophrenia and the representativeness of modern diagnostic criteria. Archives of General Psychiatry, 2016; 73(10): 1082-1092
34. Parnas SJ. The RDoc program: psychiatry without psyche? World Psychiatry, 2014;
13:46-67.
35. Gottesman II, Shields J. Schizophrenia: The Epigenetic puzzle. Cambridge, England:
Cambridge University Press, 1982
36. Ketty SS, Wender PH, Jacobsen B, Ingaham IJ, Jansson L, Faber B et al. Mental illness in the biological and adoptive relatives of schizophrenia adoptees. Archives of General Psychiatry, 1994; 51:442-455.
104
37. Riley B, Kendler KS. Molecular genetic studies of schizophrenia: European Journal of Human Genetics, 2006; 14: 669 -680.
38. Shaw SH, Kelly M, Smith AB, Shields G, Hopkins PJ, Loftus J et al. A genome-wide search for schizophrenia susceptibility genes. American Journal of Medical Genetics, 1998; 81(5):364-376.
39. Yang J, Lee SH, Goddard ME, Visscher PM. “GCTA: a tool for genome-wide complex trait analysis”. The American Journal of Human Genetics, 2o11; 88(1):76-82.
40. Lee SH, DeCandia TR, Ripke S. Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nature Genetics, 2014; 44:247-250.
41. Mowry BJ, Gratten J. The emerging spectrum of allelic variation in schizophrenia:
current evidence and strategies for the identification and functional characterization of common and rare variants. Molecular Psychiatry, 2013;18: 38-52
42. Rudin E. Zur Vererbung und Neuenstebung der Dementia Praecox. Berlin: springer;
1916.
43. O’Rourke DH, Gottesman II, Saurez BK, Rice J, Reich T. Refutation of the single locus model in the aetiology of schizophrenia. American Journal of Human Genetics, 1982;
33:630-649.
44. Bebbington P, McGuffin P. Schizophrenia: the major issues. Heinemann professional publishing, 1988.
45. Howes OD, Kapur S. Schizophrenia Bulletin, 2009; 35:549-562.
46. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Selby JP, Bowers M. Increased striatal dopamine transmission in schizophrenia: conformation in a second cohort. American Journal of Psychiatry, 1998; 155: 761-767.
47. Harrison PJ. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain, 1999; 122:593-624.
48. Crow TJ. Schizophrenia as a failure of hemispheric dominance for language. Trends in Neuroscience, 1997; 20:339-343.
49. Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? Editorial British Medical Journal 1987; 295: 681-682.
105
50. Abrahao AL, Focaccia R, Gattaz WF. “Childhood meningitis increases the risk for adult schizophrenia.” World Journal of Biological Psychiatry, 2005; 6(2):44–48, 2005.
51. McGory PD, Yung AR, Bechdolf A, Amminger P. Back to the future: predicting and reshaping the course of psychotic disorder. Archives of General Psychiatry, 2008; 65:25-27.
52. Liddle F. “Syndromes of schizophrenia on factor analysis,” The British Journal of Psychiatry, 1992; 161:861.
53. Liddle F, Barnes TRE, “Syndromes of chronic schizophrenia,” The British Journal of Psychiatry, 1990; 157:558–561.
54. Engel GL. The clinical application of the biopsychosocial model. American Journal of Psychiatry, 1980; 137(5):535-544.
55. National Institute for Health and Clinical Excellence Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care National Clinical Practice Guideline 82London, UK: National Institute for Health and Clinical Excellence; 2009.
56. Gutierrez-Recacha P, Chisholm D, Haro JM, Salvador-Carulla L, Ayuso-Mateos JL.
Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain. Acta Psychiatrica Scandinavica, 2004; 32:29–38.
57. Lieberman RP, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Journal Clinical Psychiatry, 1990; 57(9):5-9.
58. Boydell J, Van-Os J, Murray RM. The outcome of psychotic illness. In: Lieberman J, Murray RM. The comprehensive care of schizophrenia: Donitz, 2001; 37-59.
59. Van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L et al. Standardized remission criteria in schizophrenia. Acta Psychiatrica Scandinavica, 2006; 113:91-95.
60. Leucht S, Lassen R. The concept of remission and recovery in schizophrenia.
Pharmacopsychiatry, 2006; 39:161-170.
61. Harvey PD, Bellack AS. Towards a terminology for functional recovery in schizophrenia:
is functional remission a viable concept? Schizophrenia Bulletin, 2009; 35:300-306.
106
62. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychological Medicine, 2006; 36:1349-1362.
63. Farden A, Nesvag R, Marder SR. Definitions of the term ‘recovered’ in schizophrenia and other disorders. Psychopathology, 2008; 35:300-306.
64. Shrivastava A, Johnston M, Shah N, Bureau Y. Redefining outcome measures in schizophrenia: integrating social and clinical parameters. Current opinion in Psychiatry, 2010; 23:120-126.
65. Warner R. Recovery of schizophrenia: Psychiatry and Political Economy. London:
Routledge, 2004.
66. Strauss JS, Carpenter WT. The prediction of outcome in schizophrenia. Archives of General Psychiatry, 1977; 34:159-163.
67. Van-Os J, Kapur S. Schizophrenia. Lancet, 2009; 374:635-645.
68. McGorry PD, Nelson B, Goldstone S, Yung AR. Clinical Staging: A heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Canadian Journal of Psychiatry, 55:486-497.
69. Ciompi L. The natural history of schizophrenia in the long-term. British Journal of Psychiatry, 1980; 136:413-420.
70. Huber G, Gross G, Schuttler R, Linz M. Longitudinal studies of schizophrenia patients.
Schizophrenia Bulletin, 1980; 6:592-605.
71. Shepherd M, Watt D, Fallon IRH, Smeeton N. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenia Cambridge, United Kingdom: Cambridge University press 1989.
72. Makanjuola RO. Clinical and socio-cultural parameters in Nigerian psychiatric patients.
A prospective study. Acta Psychiatrica Scandinivica, 1985;72(6):512-521.
73. Gureje O, Bamidele R. Thirteen-year social outcome among Nigerian out-patients with schizophrenia. Social Psychiatry and Psychiatry Epidemiology, 1999; 34(3):147-151.
74. Obembe A, Famuyiwa O, Bebbington P. Outcome of functional psychoses in metropolitan Lagos, Nigeria. East African Medical Journal, 1995;74(4):234-237
75. Adegbaju DA, Olagunju AT, Uwakwe K. A comparative analysis of disability in individuals with bipolar affective disorder and schizophrenia in a sub-saharan Africa
107
mental hospital: towards evidence guided rehabilitation intervention. Social Psychiatry and Psychiatric Epidemiology, 2013; 48(9):1405-1415.
76. Akinsulore A, Mapayi BM, Aloba OO, Ibidunni O, Fatoye FO, Makanjuola ROA.
Disability assessment as an outcome measure: a comparative study of Nigerian
outpatients with schizophrenia and healthy control. Annals of General Psychiatry, 2015;
14:40
77. Geddes J, Mercer G, Frith CD, Macmillian F, Owens DGC, Johnston EC. Prediction of outcome following a first-episode of schizophrenia: a follow-up study of Northwick Park first-episode study subjects. British Journal of Psychiatry, 1994; 165:664-668.
78. Schennach-Wolff R, Juger M, Seemuller F, Obermeier M, Messer T, Laux G et al.
Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Current Opinion in Psychiatry, 2011; 24(2):114-121.
79. Butzlaff RL, Hooley JM. Expressed emotions and psychiatric relapse: a meta-analysis.
Archives of General Psychiatry, 1998; 55:547-552.
80. Tsang HWH, Leung AY, Chung RCK, Bell M, Cheung W. Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998. Australian and New Zealand Journal of Psychiatry, 2010; 44:495-504.
81. Wiersma D, Nienhuis FJ, Sloof CJ, Giel R. Natural course of schizophrenia disorders. A 15-year follow-up of a Dutch incidence cohort. Schizophrenia Bulletin, 1998; 2475-2485.
82. Harrison G, Croudace T, Mason P, Glazebrook C, Medley I. Predicting the long-term outcome of schizophrenia. Psychological Medicine, 1996; 26:697-705.
83. Fenton WS, McGlashan TH. Prognostic scale for chronic schizophrenia. Schizophrenia Bulletin, 1987; 13:277-286.
84. Lambo TA. Further neuropsychiatric observations in Nigeria, with comments on the need for epidemiological study in Africa. British Medical Journal, 1960; 1696-1704.
85. Susser E, Collins P, Schanzer B, Varma VK, Gittelman M. Topics for our time: can we learn from the care of persons with mental illness in developing countries? American Journal of Public Health, 1996; 86:926-928.
86. Raymond T, Lloyd B, Marje L, Tom KJC. Perceived emotional support in remission:
results from an 18-month follow-up of patients with early episode psychosis. Social Psychiatry and Psychiatric Epidemiology, 2013; 48(12):1897-1904.
108
87. Buchanan J. Social support and schizophrenia: a review of literature. Archives of Psychiatric Nursing, 1995; 9(2):68-76.
88. Kurihara T, Kato M, Reverger R. Eleven-year clinical outcome of schizophrenia in Bali.
Acta Psychiatrica Scandinavica, 2005; 112:456-462.
89. Kurihara T, Kato M, Reverger R. Outcome of schizophrenia in a non-industrialized society: comparative study between Bali and Tokyo. Acta Psychiatrica Scandinavica, 2000; 101:148-152.
90. Bowie CR, Reichenberg A, Patternson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. American Journal of Psychiatry, 2006; 163:418-425.
91. Brown KW, White T. Syndrome of chronic schizophrenia and some clinical correlates.
British Journal of Psychiatry, 1992; 161:317-322.
92. Liddle PF, Morris DL. Schizophrenic syndrome and frontal lobe performance. British Journal of Psychiatry, 1991; 158:340-345.
93. Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE. Course of treatment response in first-episode and chronic schizophrenia. American Journal of Psychiatry, 1996; 153:519-525.
94. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double blind, placebo-and haloperidol-controlled trial with olanzapine. American Journal of Psychiatry, 1997; 154:466-474.
95. Kurtz MM. Symptoms versus neurocognitive skills as correlates of every day functioning in severe mental illness. Expert Review Neurotherapeutics, 2006; 6:47-56.
96. Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophrenia Research, 2009; 113:189-199.
97. Shamsi S, Lau A, Lencz T, Burdick KE, Derosse P, Brenner R et al. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophrenia Research, 2011; 126:257-264.
98. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. American Journal of Psychiatry, 2005; 162:495-506.
109
99. Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J. Association between changes on the Negative Symptom Assessment Scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Research, 2009; 169:97-100.
100. Reyes MM, Quinonez RM, Villalvilla TD, Lomba P, Fernando AP, Sosa MV. Family transmission of positive and n negative symptoms in familial and sporadic schizophrenia.
Actas Espanolas de Psiquiatria, 2004; (6):353-357.
101. Malaspina D, Goezt R, Scott Y, Berman A, Harkary-Friedman J, Printz D, et al.
Relation of familial schizophrenia to negative symptoms but not to the deficit syndrome. American Journal of Psychiatry, 2000; 157(6):994-1003.
102. Wyatt RJ. Neuroleptics and natural course of schizophrenia. Schizophrenia Bulletin, 1991; 17:325-351.
103. Black K, Peter L, Rui Q, Milliken H, Kopala LC. Duration of untreated psychosis predicts treatment outcome in an early psychosis program. Schizophrenia Research, 2001; 47:215-222.
104. Verdox H, Liraud F, Bergey C, Assens F, Abalan F, Van-Os J. Is the association between duration of psychosis and outcome confounded? A two year follow-up study of first-admitted patients. Schizophrenia Research, 2001; 49:231-241.
105. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. American Journal of Psychiatry, 2005; 162:1785-1804.
106. Linszen D, Lenior R, De-Haan L, Dingemans P, Gersons B. Early intervention, untreated psychosis and the course of early schizophrenia. British Journal of Psychiatry, 1998; 172:84-89.
107. Lieberman JA, Sheitman B, Chakos M, Robinson D, Schooler N, Keith S. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. Journal Clinical Psychopharmacology, 1998; 18:20S-24S.
108. Birchwood M, Todd P, Jackson C. Early intervention in psychosis: the critical period hypothesis. British Journal of Psychiatry, 1998; 17:253-259.
109. McGlash TH. Duration of untreated psychosis in first episode schizophrenia: marker or determinant of course? Biological Psychiatry, 1999; 46:899-907.
110
110. Velakoulis D, Wood SJ, Smith DJ. Increased duration of illness is associated with reduced volume in right mesial temporal/anterior cingulate grey matter in patients with chronic schizophrenia. Schizophrenia Bulletin, 2001; 57:43-49.
111. Malla AK, Mittal C, Lee m. computerized tomography of the brain morphology of patients with first-episode schizophrenic psychosis. Journal of Psychiatry and Neuroscience, 2002; 27:350-358.
112. Norman RMG, Lewis SW, Marshall M. Duration of untreated psychosis and its relationship to clinical outcome. British Journal of Psychiatry, 2005; 187(48):19-23.
113. Norman RMG, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychological Medicine, 2001; 31:381-400.
114. Boys A, Marsden J, Stillwell G, Hatchings K, Griffiths P, Farrell M. Minimizing respondent attrition in longitudinal research: practical implications from a cohort study of adolescent drinking. Journal Adolescence, 2003; 26(3):363-373.
115. Miller R, Wright D. Detecting and correcting attrition bias in longitudinal family research. Journal of Marriage and Family, 1995; 57:921-946.
116. Schaffer RH: Social Development. 1996, Blackwell Publishers Incoporated, Oxford.
117. Fischer EH, Dornelas EA, Goethe JW: Characteristics of people lost to attrition in psychiatric follow-up studies. Journal of Nervous and Mental Disorder, 2001; 189: 49-55.
118. Bjerkeset O, Nordahl HM, Larsson S, Dahl AA, Linaker O: A 4-year follow-up study of syndromal and sub-syndromal anxiety and depression symptoms in the general population. Social Psychiatry and Psychiatric Epidemiology, 2008; 43: 192-199.
119. Araoye MO. Research methodology with statistics for health and social sciences.
Nathadox Publishers, Ilorin. 2003. 218-222.)
120. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR.
Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry, 2005; 162:441-499.
121. Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia Bulletin, 2012; 39(6):1296-1306.
111
122. Goldman HH, Skodol AE, Lave TR. Revisiting Axis V for DSM-1V: a review of meaures of social functioning. American Journal of Psychiatry, 1992; 149(9):1148-1156.
123. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S et al. Predictors of relapse following response from first-episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 1999; 50:241-247.
124. Tonsing K, Zimet GD, Tse S. Assessing social support among South Asian: the multidimensional scale of perceived social support. Asian Journal of Psychiatry, 2012;
5(2):164-168.
125. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Amorim P, Janavs J, Weiller E et al.
The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview. Journal of Clinical Psychiatry, 1998; 20:22-33.
126. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports, 1962; 10:799-812.
127. Zanello A, Berthoud L, Ventura J, Merlo MCG. The Brief Psychiatric Rating Scale;
factorial structure and its sensitivity in the treatment of outpatients with unipolar depression. Psychiatry Research, 2013; 210(2):626-633.
128. Bawo J, Agbonile IO, Okolo M, Lawani AO, Omoaregba JO. Prevalence of Toxoplasma gondii infection among individuals with severe mental illness inn Nigeria: a case control study. Pathogens and Global Health, 2013; 107(4):189-193.
129. Andreasen NC. The Scale for the Assessment of Negative Symptoms. Iowa City:
University of Iowa, 1983.
130. Peralta V, Cuesta MJ. Positive and Negative symptoms/syndromes in schizophrenia:
reliability and validity of different diagnostic systems. Psychological Medicine, 1995;
25:43-50.
131. Okewole AO, Abiodun OA, Makanjuola RO. Cognitive functioning among patients with schizophrenia in a Nigerian hospital: a comparison with mood disorder.
Schizophrenia Research: Cognition, 2014; 1(3):155-159.
112
132. Guy W. Clinical Global Impression. In: Early Clinical Drug Evaluation Unit Assessment Manual for psychopharmacology (revised). National Institute of Mental Health, Rockville, MD 1976; 217-221.
133. Haro JM, Kamath SA, Ochoa S. The Clinical Global Impression Schizophrenia Scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatrica Scandinavica, 2003; 107:16-23.
134. Levine SZ, Leucht S. Psychometric analysis in support of shortening the scale for the assessment of negative symptoms. European Neuropsychopharmacology, 2013; 23:1051-1056.
135. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition American Psychiatric Association, Washington DC; 1994.
136. World Health Organization. Measuring health and disability: Manual for WHO Disability Assessment Schedule (WHODAS 2.0), World Health Organization, 2010, Geneva.
137. National Institute of Mental Health (NIMH) Genetics Initiative: Family Interview for Genetic Studies (FIGS). Rockville: National Institute of Mental Health, 1992.
138. Andreasen NC, Rice J, Endicott J, Reich T, Coryell W. The family history approach to diagnosis. Archives of General Psychiatry, 1986; 43:421-429.
139. Chen WJ, Liu SK, Chang CJ, Lien YJ, Chang YH, Hwu HG. Sustained attention deficits and schizotypal personality features in nonpsychotic relatives of schizophrenia patients.
American Journal of Psychiatry, 1998; 155:1214-1220.
140. Zimet GD, Dahlem NW, Zimet SG, Farley GK: the multidimensional scale of perceived social support. Journal of Personality Assessment, 1988; 52:30-41.
141. Hamza A, Al-Sadat AMN, Yim LS. Measurinng perceived social support in stroke survivors: linguistic validation of the Multidimensional Scale of Perceived Social Support (MSPSS) in Hausa (Nigerian) language. South African Journal of Occupational therapy, 2012; 42(3):26-31.
142. Browne G, Courtney M. Schizophrenia, housing, and supportive relationships.
International Journal of Mental Health Nursing, 2007; 10(2)73-80.